Abstract Type 2 diabetes (T2D), cardiovascular disease (CVD) and chronic kidney disease
(CKD), are recognized among the most disruptive public health issues of the current century …

Diverse subsets of endothelial progenitor cells (EPCs) are used for the treatment of ischemic
diseases in clinical trials, and circulating EPCs levels are considered as biomarkers for …

Type 2 diabetes is characterized by a two-to fourfold increased risk of cardiovascular
disease. This is generally attributed to the adverse effects of hyperglycemia and oxidative …

Critical limb ischemia (CLI), the most severe form of peripheral artery disease, is
characterized by pain at rest and non-healing ulcers in the lower extremities. For patients …

Human endothelial progenitor cells (EPCs) have been generally defined as circulating cells
that express a variety of cell surface markers similar to those expressed by vascular …

• Introduction• The proof‐of‐concept in vivo: the cell, the read‐out and the animal model‐The
CEPC: Still a putative cell‐Do CEPCs play an essential role in vascular (patho) physiology …

Long-term diabetes increases the likelihood of developing secondary damage to numerous
systems, and these complications represent a substantial cause of morbidity and mortality …

OBJECTIVE Vasculoprotective endothelial progenitor cells (EPCs) are regulated by stromal-
derived factor-1α (SDF-1α) and are reduced in type 2 diabetes. Because SDF-1α is a …

Cell therapy is a promising option for treating ischemic diseases and heart failure. Adult
stem and progenitor cells from various sources have experimentally been shown to augment …

BACKGROUND: Peripheral arterial disease (PAD) is a common cause of disability and
mortality. Up to one third of patients are not susceptible to traditional revascularization and …